{
  "nctId": "NCT03698409",
  "briefTitle": "Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine.",
  "officialTitle": "Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine. A Randomized, Double-blind Trial.",
  "protocolDocument": {
    "nctId": "NCT03698409",
    "filename": "Prot_SAP_001.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2019-11-13",
    "uploadDate": "2022-05-08T11:11",
    "size": 143117,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03698409/document/Prot_SAP_001.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE4"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "TRIPLE",
  "enrollmentInfo": {
    "enrollmentCount": 68,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2019-01-01",
    "completionDate": "2019-08-01",
    "primaryCompletionDate": "2019-08-01",
    "firstSubmitDate": "2018-10-04",
    "firstPostDate": "2018-10-09"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Patients with diagnosis of chronic migraine receiving FDA-approved treatment with OnabotulinumtoxinA injection as per standard protocol. Standard protocol consists of 31 injection sites, with total dose ranging from 155 u to 195u.\n\nExclusion Criteria:\n\n* Subjects whom OnabotulinumtoxinA injections deviate from standard protocol for any reason, such as head/neck infection, head deformity, recent surgeryâ€¦etc.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "79 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Verbal Pain Scale",
        "description": "Difference in verbal pain scale (0 to 10, 0 indicates no pain, and 10 indicates most severe pain)",
        "timeFrame": "Immediately after intervention, an average of 2 minutes"
      }
    ],
    "secondary": [
      {
        "measure": "Headache-day Frequency",
        "description": "Difference in headache-days in the first week following the procedure",
        "timeFrame": "1 week"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "PHASE4"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 44,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:52.485Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}